2023-12-04: Mindray has completed acquisition of a controlling stake in DiaSys Diagnostic Systems GmbH

Upon completion of the transaction, DiaSys will be integrated into Mindray's system. With a unified team, both parties will cooperate to enhance products, facilitate joint development, expand platforms, and smoothly implement the integration plan. This strategic alignment aims to substantially strengthen the joint global competitive edge in the in-vitro diagnostics business.



“We are thrilled by becoming part of Mindray, to enhance the capabilities and to expand the global footprint of both parties involved! Both companies are ready for intensive future growth and collaboration, and will support each other to optimize market coverage in their common future,” says Dr. Günther Gorka, Founder of DiaSys.

Established in 1991 and headquartered in Holzheim, Germany, DiaSys looks back on more than three decades of successful development and global marketing of clinical chemistry and immunoturbidimetric reagents. As global pioneer in liquid-stable, ready-to-use clinical chemistry reagents, DiaSys has as well established a strong reputation as a manufacturer of fully and semi-automated lab analyzers and near-patient diagnostic instruments. The company has built an extensive global supply chain system, with production facilities across Europe, APAC, and Latin America. The company maintains its own development and production facilities for calibrators and controls, which complete the portfolio of high-quality products. Customers in more than 140 countries have trusted these state-of-the-art reagents, lab systems and service. By providing innovative products, DiaSys will remain a reliable partner to global healthcare systems.

 “We are delighted to welcome DiaSys as a member of the Mindray family! The acquisition will allow us to expedite the development of our overseas supply chain platform, provide access to a talented international team, and enhance our in-vitro diagnostics offering. Mindray is committed to offering resources and support to DiaSys while leveraging our extensive experience in global integration to achieve effective synergistic growth for both companies.” says Wu Hao, President of Mindray.

Mindray is a leading high-tech medical device manufacturer in China, and one of the global leaders in medical innovation. The company’s business covers patient monitoring and life support, in-vitro diagnostics and medical imaging system. Mindray is committed to creating customer value with comprehensive solutions through cutting-edge technological innovation, improving medical conditions, and enhancing efficiency. In October 2018, Mindray was listed on the Shenzhen Stock Exchange's ChiNext board (SZSE: 300760).